Zero Candida Technologies

AI-enabled Blue-light Vaginal Device for at-home VVC Treatment and Monitoring

Health Tech & Life Sciences
Public on TSXV on Nov 2024

Company Overview

Snapshot

Founded in January 2022 by Eli Ben Haroosh and Asher Holzer, Zero Candida Technologies operates with 11–50 employees. The company became public on the TSX Venture Exchange in November 2024, marking a significant milestone in its development.

Business overview

Zero Candida Technologies (ZCT) is a FemTech company developing an AI-enabled, tampon-like medical device that utilizes a controlled blue light source to treat Vulvo-Vaginal Candidiasis (VVC). This technology aims to destroy the Candida fungus with high efficacy and without side effects, offering a novel solution for at-home treatment and monitoring. The device is designed to collect and transmit treatment data in real-time to physicians, enabling remote care, personalized treatment, and continuous monitoring. Zero Candida Technologies operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics for women's health.

Strategic signal

In June 2026, Zero Candida Technologies was granted Patent No. 12654025B2, a meaningful milestone that reflects the company's commitment to innovation and technology. This patent validation signals strong intellectual property protection for its therapeutic device, enhancing its competitive position in the FemTech and medical device markets and providing a clear growth catalyst for investors.

Company Intelligence Q&A

When did Zero Candida Technologies go public?
Zero Candida Technologies became public on the TSX Venture Exchange in November 2024.
What significant intellectual property milestone did Zero Candida Technologies achieve in June 2026?
In June 2026, Zero Candida Technologies was granted Patent No. 12654025B2, reflecting its commitment to innovation and technology.
What was the outcome of Zero Candida's clinical trials in March 2023?
In March 2023, Zero Candida reported a 99.99% success rate in its breakthrough Candida treatment.
What operational milestone did Zero Candida achieve in October 2025?
In October 2025, Zero Candida achieved design freeze and began prototype production of its ZC-001 therapeutic device.
What production scaling did Zero Candida achieve in February 2026?
In February 2026, Zero Candida scaled production to 250 ISO 13485 clinical-grade prototypes of its ZC-001 therapeutic device.

External links